Document Detail


Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
MedLine Citation:
PMID:  19285266     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Both agonists (e.g. Delta(9)-tetrahydrocannabinol, nabilone) and antagonists (e.g. rimonabant, taranabant) of the cannabinoid type-1 (CB(1)) receptor have been explored as therapeutic agents in diverse fields of medicine such as pain management and obesity with associated metabolic dysregulation, respectively. CB(1) receptors are widely distributed in the central nervous system and are involved in the modulation of emotion, stress and habituation responses, behaviours that are thought to be dysregulated in human psychiatric disorders. Accordingly, CB(1) receptor activation may, in some cases, precipitate episodes of psychosis and panic, while its inhibition may lead to behaviours reminiscent of depression and anxiety-related disorders. The present review discusses these side-effects, which have to be taken into account in the therapeutic exploitation of the endocannabinoid system.
Authors:
Fabrício A Moreira; Maximilian Grieb; Beat Lutz
Related Documents :
23488566 - Expression of histamine receptor hrh3 and hrh4 in rat brain endothelial cells.
24733016 - Gaba and topiramate inhibit the formation of human macrophage-derived foam cells by mod...
23034456 - Functional selectivity in serotonin receptor 2a (5-ht2a) endocytosis, recycling and pho...
17567776 - Presynaptic inhibition of gabaa receptor-mediated unitary ipsps by cannabinoid receptor...
2749256 - The periaqueductal gray matter mediates opiate-induced immunosuppression.
10720616 - Intrathecal administration of an nmda or a non-nmda receptor antagonist reduces mechani...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Best practice & research. Clinical endocrinology & metabolism     Volume:  23     ISSN:  1878-1594     ISO Abbreviation:  Best Pract. Res. Clin. Endocrinol. Metab.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-03-16     Completed Date:  2009-05-26     Revised Date:  2012-11-07    
Medline Journal Info:
Nlm Unique ID:  101120682     Medline TA:  Best Pract Res Clin Endocrinol Metab     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  133-44     Citation Subset:  IM    
Affiliation:
Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 6, 55099 Mainz, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Affect / drug effects
Animals
Anxiety Disorders / chemically induced,  drug therapy*
Depressive Disorder / chemically induced,  drug therapy*
Endocannabinoids / physiology
Humans
Piperidines / adverse effects*
Pyrazoles / adverse effects*
Receptor, Cannabinoid, CB1 / agonists*,  antagonists & inhibitors*
Tetrahydrocannabinol / adverse effects*,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Endocannabinoids; 0/Piperidines; 0/Pyrazoles; 0/Receptor, Cannabinoid, CB1; 158681-13-1/rimonabant; 1972-08-3/Tetrahydrocannabinol; 56496-90-3/nabilone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.
Next Document:  Thrombosis and cancer: Trousseau syndrome revisited.